Want to see AU:NOX full AI Analyst Report?
NOX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.99%)
At close: 4:00 PM EST
AU$0.09
>-AU$0.01(-8.99%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.14
Previous CloseN/A
Volume154.85K
Average Volume (3M)123.50K
Market Cap
AU$25.19M
Enterprise ValueAU$28.12M
Total Cash (Recent Filing)AU$91.40K
Total Debt (Recent Filing)AU$4.25M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology R&D PipelineA clear, focused strategy on oncology and therapies that enhance radiotherapy is a durable business-strength. Specialization supports deep domain expertise, clearer go-to-market and partnership fits with larger oncology players, and potential for differentiated clinical assets that remain relevant over multi-year development cycles.
Top-line Recovery In 2025A ~20% revenue rebound in 2025 versus 2024 signals structural improvement in commercial or milestone receipts rather than pure volatility. For a small biotech, sustained revenue inflection can extend runway, validate certain programs, and materially change financing needs over a multi‑quarter horizon if trend persists.
Improved Free Cash Flow Versus Prior YearYear‑over‑year improvement in free cash flow suggests management is nudging the cash profile in the right direction, via cost control or revenue milestones. While still negative, this reduces the rate of runway depletion and lowers near‑term external funding pressure if the improvement continues.
Bears Say
Heavy, Persistent Cash BurnConsistent negative operating and free cash flow establishes a persistent dependency on external financing. That reliance increases dilution risk and constrains strategic choices (e.g., partnering, larger trials). Over several quarters this structural cash drain can impede program advancement if funding gaps appear.
Weakened Balance Sheet And High LeverageMaterial balance‑sheet deterioration and ~3.6x debt-to-equity indicate elevated solvency and refinancing risk. High leverage reduces flexibility to fund R&D internally, raises interest/service obligations, and makes the company more vulnerable to funding shocks, affecting multi‑quarter strategic execution.
Persistent Large Losses And Negative Gross ProfitNegative gross profit and chronically large operating losses demonstrate the core business is not yet economically viable. This structural unprofitability pressures returns on capital and means fundamental improvement must come from material commercial scaling or cost base transformation to reach sustainable margins.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.05 and its highest was AU$0.14 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$25.19M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NOX Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.13%
Trailing 12-Months
Company Description
Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―